Lisavanbulin is a synthetic compound that belongs to the class of small-molecule inhibitors, specifically designed to target the cytoskeleton of cells. It acts primarily as a microtubule destabilizer, which interferes with the normal function of microtubules, essential components of the cell's structural framework. This mechanism of action is particularly relevant in the context of cancer treatment, as it can disrupt the mitotic process, leading to cell cycle arrest and apoptosis in rapidly dividing cancer cells. Lisavanbulin has been investigated for its potential therapeutic applications in various malignancies, showcasing a promising profile in preclinical and clinical studies. The compound is characterized by its unique chemical structure, which contributes to its biological activity and specificity. Additionally, its pharmacokinetic properties, including absorption, distribution, metabolism, and excretion, are critical for determining its efficacy and safety in clinical settings. As research continues, Lisavanbulin may offer new avenues for targeted cancer therapies, particularly in cases resistant to conventional treatments.

Lisavanbulin

1263384-43-5: Lisavanbulin is a synthetic compound that belongs to the class of small-molecule inhibitors, specifically designed to target the cytoskeleton of cells. It acts primarily as a microtubule destabilizer, which interferes with the normal function of microtubules, essential components of the cell's structural framework. This mechanism of action is particularly relevant in the context of cancer treatment, as it can disrupt the mitotic process, leading to cell cycle arrest and apoptosis in rapidly dividing cancer cells. Lisavanbulin has been investigated for its potential therapeutic applications in various malignancies, showcasing a promising profile in preclinical and clinical studies. The compound is characterized by its unique chemical structure, which contributes to its biological activity and specificity. Additionally, its pharmacokinetic properties, including absorption, distribution, metabolism, and excretion, are critical for determining its efficacy and safety in clinical settings. As research continues, Lisavanbulin may offer new avenues for targeted cancer therapies, particularly in cases resistant to conventional treatments.

<p>Lisavanbulin (BAL-101553) is a prodrug of Avanbulin (BAL 27862), a microtubule-targeting agent. It exhibits antitumor activity, particularly effective against tumors with high expression of end-binding protein 1.</p>

CAS 1263384-43-5

Lisavanbulin

Lisavanbulin

Ref: TM-T88188